Police Arrest Omolara Ogundiran, Sister and Witness in Offa Robbery Trial

3rd February 2024

In a surprising turn of events during the ongoing trial related to the infamous Offa robbery incident in Kwara State, Omolara Ogundiran, the sister and a key witness for one of the accused individuals, found herself in police custody while in court. This development unfolded during the trial of Ayoade Akinnibosun, Azeez Salahudeen, Niyi Ogundiran, Ibikunle Ogunleye, and Adeola Abraham on February 2, as reported by RALD News Media.

Omolara Ogundiran, a graduate of Ire Polytechnic and the younger sister of the fifth defendant, Niyi Ogundiran, was called in as a witness by the defense counsel during the proceedings. Her testimony aimed to present a crucial piece of evidence – a receipt from a spare parts seller in Osogbo, Osun State, allegedly issued to her brother on the day of the robbery.

However, the presiding judge, Justice Halimat Salman, raised doubts about the admissibility of the receipt, deeming it a sham. The judge questioned the timing of presenting the receipt, emphasizing, "For you to now remember after about six years to present a receipt speaks volumes." Justice Salman further pointed out inconsistencies in the signature on the affidavit brought by the defense counsel and the signature on the receipt, leading to the rejection of the evidence.

In the aftermath of this decision, Omolara Ogundiran was taken into custody by the police. The legal proceedings took an unexpected turn, shedding light on the complexity and legal intricacies surrounding the Offa robbery case.

The trial, now marked by the arrest of a witness, has added another layer of complexity to an already lengthy legal battle. This development underscores the challenges and twists that continue to characterize the Offa robbery incident case. The case has been adjourned to Tuesday, April 9, 2024, allowing time for the adoption of written addresses by the counsels involved. RALD News Media will continue to closely monitor and report on further developments in this high-profile trial.